- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 87,870 | 18.06.24 09:35:40 | +0,620 | +0,71% | 88,120 | 88,290 | 87,640 | 87,250 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 969,600 | 18.06.24 08:14:43 | -6,200 | -0,64% | 971,800 | 977,600 | 969,600 | 975,800 |
